GlassScriptPhysician profile
Nicholas P Ditullio
NPI 1275597619
$1,020.19
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $108 · 2021: $298 · 2023: $43.49 · 2024: $21.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $64.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $64.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $182.49 | 2019-2020 | |
| Edwards Lifesciences Corporation | $152.50 | 2021 | |
| Veryan Medical Incorporated | $145.50 | 2021 | |
| Pfizer INC. | $76.62 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $75.78 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $73.45 | 2019 | |
| Glaxosmithkline, LLC. | $71.67 | 2019-2020 | |
| Daiichi Sankyo INC. | $65.91 | 2019-2020 | |
| Amgen INC. | $52.11 | 2019 | |
| Medicomp INC | $43.49 | 2023 | Telepatch Cardiac Monitor |
| Allergan, INC. | $36.40 | 2019 | |
| Biogen, INC. | $18.48 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.13 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Ditullio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.